| 15/10/26 | 16:00:00 | 15 Oct 2026 | | Proposed Retail Offer | PRN |
| 15/10/26 | 15:15:00 | 15 Oct 2026 | | Results of Capital Raise | PRN |
| 15/10/26 | 07:00:00 | 15 Oct 2026 | | Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million | PRN |
| 28/09/26 | 12:00:00 | 28 Sept 2026 | | 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program | GNW |
| 28/09/26 | 07:01:00 | 28 Sept 2026 | | Half-year Report | PRN |
| 28/09/26 | 07:00:00 | 28 Sept 2026 | | 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program | PRN |
| 07/09/26 | 07:00:00 | 7 Sept 2026 | | 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | PRN |
| 26/08/26 | 07:20:00 | 26 Aug 2026 | | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | GNW |
| 26/08/26 | 07:00:00 | 26 Aug 2026 | | 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | PRN |
| 22/07/26 | 07:00:00 | 22 Jul 2026 | | Grant of Options & Director/PDMR Dealing | PRN |
| 22/07/26 | 07:00:00 | 22 Jul 2026 | | Grant of Options & Director/PDMR Dealing | PRN |
| 08/07/26 | 07:00:00 | 8 Jul 2026 | | Director Appointment | PRN |
| 30/06/26 | 17:38:00 | 30 Jun 2026 | | Result of AGM & Issue of Options | PRN |
| 30/06/26 | 17:37:00 | 30 Jun 2026 | | Result of AGM & Issue of Options | PRN |
| 16/06/26 | 07:00:00 | 16 Jun 2026 | | Notice of Investor Presentation | PRN |
| 15/06/26 | 12:00:00 | 15 Jun 2026 | | 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board | GNW |
| 05/06/26 | 07:00:00 | 5 Jun 2026 | | Notice of Annual General Meeting | PRN |
| 22/05/26 | 09:10:00 | 22 May 2026 | | Director Dealing | PRN |
| 20/05/26 | 12:00:00 | 20 May 2026 | | Final Results and Notice of AGM | GNW |
| 20/05/26 | 12:00:00 | 20 May 2026 | | 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial | GNW |
| 14/05/26 | 12:00:00 | 14 May 2026 | | 4basebio Announces Appointment of Chief Financial Officer and Board Changes | GNW |
| 14/05/26 | 07:00:00 | 14 May 2026 | | Appointment of Chief Financial Officer and Board Changes | PRN |
| 11/05/26 | 12:00:00 | 11 May 2026 | | 4basebio Launches Enzymatic ssDNA Platform | GNW |
| 16/02/26 | 07:00:00 | 16 Feb 2026 | | Director Dealing | PRN |
| 11/02/26 | 15:58:00 | 11 Feb 2026 | | Director Dealing | PRN |
| 10/02/26 | 07:00:00 | 10 Feb 2026 | | Leadership Changes | PRN |
| 27/10/25 | 07:00:00 | 27 Oct 2025 | | Synthetic opDNA® utilised in Phase I/II US clinical trials | PRN |
| 10/10/25 | 11:30:00 | 10 Oct 2025 | | Result of Extraordinary General Meeting | PRN |
| 30/09/25 | 16:20:00 | 30 Sept 2025 | | Director Dealing | PRN |
| 29/09/25 | 07:00:00 | 29 Sept 2025 | | Half-year Report | PRN |
| 22/07/25 | 07:00:00 | 22 Jul 2025 | | Employee Long Term Incentive Plan and Issue of Equity | PRN |
| 08/07/25 | 10:30:00 | 8 Jul 2025 | | Director Appointment, Board Change | PRN |
| 03/07/25 | 07:00:00 | 3 Jul 2025 | | Holding(s) in Company | PRN |
| 02/07/25 | 07:00:00 | 2 Jul 2025 | | Holding(s) in Company | PRN |
| 27/06/25 | 18:05:00 | 27 Jun 2025 | | Result of AGM | PRN |
| 25/06/25 | 07:00:00 | 25 Jun 2025 | | Exercise of Options | PRN |
| 17/06/25 | 07:00:00 | 17 Jun 2025 | | Holding(s) in Company | PRN |
| 27/05/25 | 07:00:00 | 27 May 2025 | | Final Results and Notice of AGM | PRN |
